BioMarin Pharmaceutical/ US09061G1013 /
| 2024-04-26 9:59:59 PM | Chg. -1.27 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 80.92USD | -1.55% | 97,422 Turnover: 7.95 mill. |
-Bid Size: - | -Ask Size: - | 15.27 bill.USD | - | 90.91 |
Assets
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 896.7000 | 948.6820 | 1,010.8680 | 1,032.4710 | 1,035.4610 | ||||||
| Intangible Assets | 517.5100 | 491.8080 | 456.5800 | 417.2710 | 388.6520 | ||||||
| Long-Term Investments | 385.7850 | 235.8640 | 411.9780 | 285.4730 | 507.7930 | ||||||
| Fixed Assets | 2,425.9810 | 2,370.9130 | 2,747.8960 | 3,505.8010 | 3,728.9400 | ||||||
| Inventories | 475.7750 | 530.8710 | 680.2750 | 698.5480 | 776.6690 | ||||||
| Accounts Receivable | 261.3650 | 342.6330 | 377.4040 | 448.3510 | 373.3990 | ||||||
| Cash and Cash Equivalents | 598.0280 | 493.9820 | 437.4460 | 649.1580 | 587.2760 | ||||||
| Current Assets | 2,207.1440 | 2,056.2150 | 1,942.1430 | 2,342.2190 | 2,274.3850 | ||||||
| Total Assets | 4,633.1250 | 4,427.1280 | 4,690.0390 | 5,848.0200 | 6,003.3250 | ||||||
Liabilities
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | - | - | - | - | - | ||||||
| Long-term debt | 813.5210 | 830.4170 | 486.2380 | 1,075.1450 | 1,079.0770 | ||||||
| Liabilities to Banks | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 1,824.4620 | 1,459.1880 | 1,567.6580 | 1,742.0180 | 1,732.5850 | ||||||
| Share Capital | .1760 | .1780 | .1800 | .1820 | .1840 | ||||||
| Total Equity | 2,808.6630 | 2,967.9400 | 3,122.3810 | 4,106.0020 | 4,270.7400 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 4,633.1250 | 4,427.1280 | 4,690.0390 | 5,848.0200 | 6,003.3250 | ||||||
Income Statement
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,313.6460 | 1,491.2120 | 1,704.0480 | 1,860.4550 | 1,846.2750 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | -14.7000 | -123.5240 | -100.4570 | -36.7650 | -82.3410 | ||||||
| Interest Income | -27.8540 | -20.8330 | -.7120 | -12.6990 | -4.8550 | ||||||
| Income Before Taxes | -35.8750 | -142.7050 | -94.8110 | -42.3220 | -75.3500 | ||||||
| Income Taxes | 81.1670 | -65.4940 | -70.9630 | -901.4220 | -11.2700 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | -117.0420 | -77.2110 | -23.8480 | 859.1000 | -64.0800 | ||||||
Per Share
Cash Flow
| 2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -8.7570 | 20.2080 | 48.2620 | 85.3650 | 304.5360 | ||||||
| Cash Flow from Investing Activities | -305.4590 | 264.3510 | -31.0260 | -53.6210 | -366.3130 | ||||||
| Cash Flow from Financing | 507.1450 | -388.0070 | -74.6740 | 181.1180 | -.0480 | ||||||
| Decrease / Increase in Cash | 189.6980 | -104.0460 | -56.5360 | 211.7120 | -61.8820 | ||||||
| Employees | 2,581 | 2,849 | 3,001 | 3,059 | 3,045 | ||||||
